Substituted 1,5-naphthyridines as endonuclease inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9505758
SERIAL NO

14920000

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof,

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SAVIRA PHARMACEUTICALS GMBHAUSTRIA VIENNA VIENNA VIENNA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Buschmann, Helmut Aachen, DE 94 442
Cusack, Stephen Seyssinet-Pariset, FR 33 50
Handler, Norbert Vienna, AT 19 27
Hawley, Ronald Charles Oakland, US 69 261
Sidduri, Achyutharao Newark, US 42 316
Smith, Mark Jersey City, US 353 5522
So, Sung-Sau Verona, US 76 300
Szolar, Oliver Vienna, AT 21 29
Wolkerstorfer, Andrea Vienna, AT 21 29

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 29, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00